资讯

Syphilis is one of the oldest known diseases. Approximately 209,000 cases were reported in the United States in 2023 — the highest number of reported cases since 1950 — including nearly 4000 ...
To the Editor: The BROADWAY trial by Nicholls and colleagues (July 3 issue) 1 was a pivotal evaluation of an intriguing agent. However, I am concerned about the use of placebo in patients with ...
A 54-year-old woman with infiltrating ductal carcinoma of the right breast treated with locoregional radiation presented with cough, fever, and dyspnea. CT showed fibrotic and ground-glass opacitie ...
Christopher Duggan is the director of the Center for Nutrition at Boston Children’s Hospital, a professor of pediatrics at Harvard Medical School, and a professor in the Departments of Nutrition and ...
Patients benefit from antiplatelet therapy after coronary-artery bypass grafting (CABG) for an acute coronary syndrome.
Poorly controlled hypertension is a common problem worldwide, particularly in low-resource settings. We conducted an ...
An appropriate duration of dual antiplatelet therapy after percutaneous coronary intervention for acute myocardial infarction ...
China has recently emerged as an important player in new drug development — a field traditionally dominated by the United States and Europe. This shift has implications for global access to new ...
Beta-blockers have been the initial treatment for symptomatic obstructive hypertrophic cardiomyopathy (HCM) despite limited ...
Hosted by Arjun (Raj) Manrai, Ph.D. and Andrew Beam, Ph.D., NEJM AI Grand Rounds features informal conversations with a variety of unique experts exploring the deep issues at the intersection of ...
Nicholas Bagley is a professor of law at the University of Michigan Law School. Stephen Morrissey, the interviewer, is the Executive Managing Editor of the Journal.
A rare T-cell lymphoma after chimeric antigen receptor (CAR) T-cell therapy for myeloma was linked to CCR4 overexpression and vector integration, which highlights the need for monitoring after CAR ...